Loading clinical trials...
Loading clinical trials...
Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
Conditions
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab
Intravitreal Injections of 10 mg/mL Ranibizumab
Locations
77
United States
Barnet Dulaney Perkins Eye Center
Mesa, Arizona, United States
Associated Retina Consultants
Phoenix, Arizona, United States
Arizona Retina and Vitreous Consultants
Phoenix, Arizona, United States
Retinal Consultants of Arizona
Phoenix, Arizona, United States
California Retina Consultants
Bakersfield, California, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Start Date
September 12, 2018
Primary Completion Date
May 22, 2020
Completion Date
June 9, 2021
Last Updated
October 4, 2022
NCT07308639
NCT06439576
NCT05562947
NCT05904028
NCT06213038
NCT06492863
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions